{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:44:31Z","timestamp":1792395871452,"version":"4.4.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000777","name":"University of Leeds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000777","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jgo.2025.102321","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T03:11:27Z","timestamp":1752894687000},"page":"102321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment-related cognitive changes in multiple myeloma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"16","author":[{"given":"Sumayyah","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Parrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2025.102321_bb0005","article-title":"Multiple myeloma: an overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat Care Soc Pract"},{"issue":"8","key":"10.1016\/j.jgo.2025.102321_bb0010","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jgo.2025.102321_bb0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1078155219835303","article-title":"Polypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathy","volume":"26","author":"Um\u0131t","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"10.1016\/j.jgo.2025.102321_bb0020","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/ejh.13597","article-title":"Comorbidities in multiple myeloma and implications on survival: a population-based study","volume":"106","author":"Sverrisd\u00f3ttir","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jgo.2025.102321_bb0025","series-title":"Cancer Survival in England: Adult, Stage at Diagnosis and Childhood-patients Followed up to 2018","author":"John","year":"2019"},{"issue":"10","key":"10.1016\/j.jgo.2025.102321_bb0030","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s40618-023-02091-7","article-title":"Glucocorticoids and cognitive function: a walkthrough in endogenous and exogenous alterations","volume":"46","author":"De Alcubierre","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"13","key":"10.1016\/j.jgo.2025.102321_bb0035","first-page":"2068","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood, J Am Soc Hematol"},{"issue":"4","key":"10.1016\/j.jgo.2025.102321_bb0040","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA: multiple myeloma, Gammopathies","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.jgo.2025.102321_bb0045","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the Hovon 143 study","volume":"39","author":"Stege","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jgo.2025.102321_bb0050","doi-asserted-by":"crossref","first-page":"e2021","DOI":"10.1002\/onco.13867","article-title":"Neurocognitive impairment after hematopoietic stem cell transplant for hematologic malignancies: phenotype and mechanisms","volume":"26","author":"Harrison","year":"2021","journal-title":"The Oncologist"},{"key":"10.1016\/j.jgo.2025.102321_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.phrs.2017.01.001","article-title":"Dysregulation of cytokine mediated chemotherapy induced cognitive impairment","volume":"117","author":"Ren","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jgo.2025.102321_bb0060","series-title":"Cancer Neurology in Clinical Practice: Neurological Complications of Cancer and its Treatment","first-page":"275","article-title":"Neurological complications of chemotherapy","author":"Vargo","year":"2018"},{"key":"10.1016\/j.jgo.2025.102321_bb0070","series-title":"American Society of Clinical Oncology Educational book. American Society of Clinical Oncology. Annual Meeting, Vol. 41","first-page":"e90","article-title":"Assessment and management of cognitive symptoms in patients with brain tumors","author":"Parsons","year":"2021"},{"issue":"4","key":"10.1016\/j.jgo.2025.102321_bb0075","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jgo.2025.102321_bb0080","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/0470846410.ch27(ii)","article-title":"Mini-mental state examination","author":"Cockrell","year":"2002","journal-title":"Principles and Practice of Geriatric Psychiatry"},{"issue":"1","key":"10.1016\/j.jgo.2025.102321_bb0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/SPC.0000000000000257","article-title":"A review of cognitive screening tools in cancer","volume":"11","author":"Isenberg-Grzeda","year":"2017","journal-title":"Curr Opin Support Palliat Care"},{"issue":"4","key":"10.1016\/j.jgo.2025.102321_bb0090","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jgo.2016.04.008","article-title":"Chemotherapy-related cognitive impairment in older patients with cancer","volume":"7","author":"Loh","year":"2016","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2025.102321_bb0095","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.jgo.2025.102321_bb0100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fonc.2015.00059","article-title":"A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer","volume":"5","author":"Ono","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.jgo.2025.102321_bb0105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13670-016-0182-9","article-title":"Cognition and cognitive impairment in older adults with cancer","volume":"5","author":"Magnuson","year":"2016","journal-title":"Curr Geriatr Rep"},{"issue":"1-2","key":"10.1016\/j.jgo.2025.102321_bb0110","first-page":"36","article-title":"Cognitive impairment associated with cancer: a brief review","volume":"15","author":"Pendergrass","year":"2018","journal-title":"Innov Clin Neurosci"},{"issue":"4","key":"10.1016\/j.jgo.2025.102321_bb0115","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11764-020-00870-2","article-title":"Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy","volume":"14","author":"Cerulla-Torrente","year":"2020","journal-title":"J Cancer Surviv"},{"issue":"6","key":"10.1016\/j.jgo.2025.102321_bb0120","first-page":"721","article-title":"\u2018Like a sieve\u2019: an exploratory study on cognitive impairments in patients with multiple myeloma","volume":"19","author":"Potrata","year":"2010","journal-title":"Eur J Cancer Care"},{"issue":"10","key":"10.1016\/j.jgo.2025.102321_bb0125","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/bmt.2013.61","article-title":"A systematic review and meta-analysis of changes in cognitive functioning in adults undergoing hematopoietic cell transplantation","volume":"48","author":"Phillips","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jgo.2025.102321_bb0130","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.jgo.2025.102321_bb0135","author":"Rohatgi"},{"key":"10.1016\/j.jgo.2025.102321_bb0140","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/9781119536604.ch6","article-title":"Choosing effect measures and computing estimates of effect","author":"Higgins","year":"2019","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions"},{"key":"10.1016\/j.jgo.2025.102321_bb0145","article-title":"How to obtain the P value from a confidence interval","volume":"343","author":"Altman","year":"2011","journal-title":"Bmj"},{"key":"10.1016\/j.jgo.2025.102321_bb0150","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"108602","author":"Higgins","year":"2024","journal-title":"Environ Int"},{"issue":"3","key":"10.1016\/j.jgo.2025.102321_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"issue":"4","key":"10.1016\/j.jgo.2025.102321_bb0160","first-page":"153","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"BMJ Ment Health"},{"key":"10.1016\/j.jgo.2025.102321_bb0165","series-title":"Doing Meta-analysis with R: A Hands-on Guide","author":"Harrer","year":"2021"},{"key":"10.1016\/j.jgo.2025.102321_bb0170","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","first-page":"241","article-title":"Analysing data and undertaking meta-analyses","author":"Deeks","year":"2019"},{"key":"10.1016\/j.jgo.2025.102321_bb0175","series-title":"Cognitive screening instruments: A practical approach","first-page":"139","article-title":"Montreal Cognitive Assessment (MoCA): concept and clinical review","author":"Julayanont","year":"2017"},{"issue":"2","key":"10.1016\/j.jgo.2025.102321_bb0180","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jgo.2018.08.003","article-title":"Prospective comparison of the montreal cognitive assessment (MoCA) and the mini mental state examination (MMSE) in geriatric oncology","volume":"10","author":"Rambeau","year":"2019","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2025.102321_bb0185","doi-asserted-by":"crossref","DOI":"10.2196\/36825","article-title":"A computerized cognitive test battery for detection of dementia and mild cognitive impairment: instrument validation study","volume":"5","author":"Ye","year":"2022","journal-title":"JMIR Aging"},{"issue":"5","key":"10.1016\/j.jgo.2025.102321_bb0190","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jval.2019.02.004","article-title":"PROMIS\u00ae adult health profiles: efficient short-form measures of seven health domains","volume":"22","author":"Cella","year":"2019","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jgo.2025.102321_bb0195","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jha2.231","article-title":"Patient-reported outcomes following autologous stem cell transplant for patients with multiple myeloma","volume":"2","author":"Biran","year":"2021","journal-title":"EJHaem"},{"issue":"5","key":"10.1016\/j.jgo.2025.102321_bb0200","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1002\/cam4.5331","article-title":"Remote assessment of cognitive dysfunction in hematologic malignancies using web-based neuropsychological testing","volume":"12","author":"Franco-Rocha","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.jgo.2025.102321_bb0205","series-title":"Physical Function, Cognitive Impairment, and Quality-of-life among Adults with Multiple Myeloma and Associated Plasma Cell Disorders","author":"Jensen","year":"2021"},{"issue":"23","key":"10.1016\/j.jgo.2025.102321_bb0210","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1002\/cncr.28323","article-title":"Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant","volume":"119","author":"Jones","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2025.102321_bb0215","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jgo.2019.11.007","article-title":"Screening for cognitive impairment in older adults with hematological malignancies using the Montreal Cognitive Assessment and neuropsychological testing","volume":"11","author":"Koll","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2025.102321_bb0220","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2008.07378.x","article-title":"Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study","volume":"143","author":"Lee","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2025.102321_bb0225","series-title":"Haematologica, Vol. 101","first-page":"261","article-title":"Patient-reported quality of life with ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in relapsed\/refractory multiple myeloma patients in the global, placebo-controlled TOURMALINE-MM1 study","author":"Leleu","year":"2016"},{"issue":"2","key":"10.1016\/j.jgo.2025.102321_bb0230","doi-asserted-by":"crossref","first-page":"E552","DOI":"10.1097\/NCC.0000000000000990","article-title":"Factors affecting quality of life in patients receiving autologous hematopoietic stem cell transplantation","volume":"45","author":"Mohanraj","year":"2022","journal-title":"Cancer Nurs"},{"issue":"8","key":"10.1016\/j.jgo.2025.102321_bb0235","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.bbmt.2020.05.010","article-title":"Pretransplantation cognitive dysfunction in advanced-age hematologic cancers: predictors and associated outcomes","volume":"26","author":"Root","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jgo.2025.102321_bb0240","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.clml.2022.08.002","article-title":"Longitudinal analysis of patient-reported cognitive function in multiple myeloma","volume":"22","author":"Yusuf","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jgo.2025.102321_bb0245","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-10101-9","article-title":"The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study","volume":"22","author":"Fischer","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2025.102321_bb0250","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08325-2","article-title":"Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial","volume":"21","author":"Knop","year":"2021","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.jgo.2025.102321_bb0255","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/brainsci11091166","article-title":"Chemotherapy-related differences in cognitive functioning and their biological predictors in patients with multiple myeloma","volume":"11","author":"Bury-Kami\u0144ska","year":"2021","journal-title":"Brain Sci"},{"issue":"8","key":"10.1016\/j.jgo.2025.102321_bb0260","article-title":"Evaluating treatment outcomes on health-related quality of life in multiple myeloma patients","volume":"13","author":"Kumar","year":"2024","journal-title":"Int J Life Sci, Biotechnol Pharma Res"},{"issue":"3","key":"10.1016\/j.jgo.2025.102321_bb0265","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.20.01370","article-title":"Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial","volume":"39","author":"Perrot","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2025.102321_bb0270","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bjh.17435","article-title":"Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial","volume":"194","author":"Plesner","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jgo.2025.102321_bb0275","doi-asserted-by":"crossref","first-page":"e874","DOI":"10.1016\/S2352-3026(20)30356-2","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial","volume":"7","author":"Roussel","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.jgo.2025.102321_bb0280","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/ejh.13379","article-title":"Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial","volume":"104","author":"Schjesvold","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jgo.2025.102321_bb0285","article-title":"Tool for detecting publication bias goes under spotlight","author":"Cressey","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jgo.2025.102321_bb0290","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/08919887211023591","article-title":"The role of cognitive self-report measure type in predicting cognitive decline among older adults: a systematic review","volume":"35","author":"Wion","year":"2022","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"8","key":"10.1016\/j.jgo.2025.102321_bb0295","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/jech-2017-210116","article-title":"Cognitive function trajectories and their determinants in older people: 8 years of follow-up in the English Longitudinal Study of Ageing","volume":"72","author":"Zaninotto","year":"2018","journal-title":"J Epidemiol Community Health"},{"issue":"2","key":"10.1016\/j.jgo.2025.102321_bb0300","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5770\/cgj.24.456","article-title":"Aging in place: challenges of older adults with self-reported cognitive decline","volume":"24","author":"Mayo","year":"2021","journal-title":"Can Geriatr J"},{"key":"10.1016\/j.jgo.2025.102321_bb0305","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40487-021-00140-w","article-title":"Current challenges faced by cancer clinical trials in addressing the problem of under-representation of older adults: a narrative review","volume":"9","author":"Parks","year":"2021","journal-title":"Oncol Ther"},{"key":"10.1016\/j.jgo.2025.102321_bb0310","doi-asserted-by":"crossref","first-page":"1387251","DOI":"10.3389\/fonc.2024.1387251","article-title":"Cancer related cognitive impairment: a downside of cancer treatment","volume":"14","author":"Demos-Davies","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jgo.2025.102321_bb0315","series-title":"Seminars in oncology nursing, Vol. 36, No. 1","first-page":"150977","article-title":"Cognitive rehabilitation for cognitive dysfunction after cancer and cancer treatment: implications for nursing practice","author":"Von Ah","year":"2020"},{"issue":"9","key":"10.1016\/j.jgo.2025.102321_bb0320","first-page":"797","article-title":"An overview of chemotherapy-related cognitive dysfunction, or'chemobrain'","volume":"28","author":"Moore","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.jgo.2025.102321_bb0325","article-title":"Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study","author":"Kerkmann","year":"2024","journal-title":"The Oncologist"},{"issue":"5","key":"10.1016\/j.jgo.2025.102321_bb0330","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1200\/JCO.2016.68.5826","article-title":"Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study","volume":"35","author":"Janelsins","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2025.102321_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.770413","article-title":"Long-term cognitive dysfunction in cancer survivors","volume":"8","author":"Orsz\u00e1ghov\u00e1","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"7","key":"10.1016\/j.jgo.2025.102321_bb0340","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.ctrv.2012.05.002","article-title":"Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review","volume":"38","author":"Hutchinson","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"24","key":"10.1016\/j.jgo.2025.102321_bb0345","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1002\/cncr.34479","article-title":"Annual report to the nation on the status of cancer, part 1: National cancer statistics","volume":"128","author":"Cronin","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2025.102321_bb0350","author":"Cancer Research UK"},{"issue":"5","key":"10.1016\/j.jgo.2025.102321_bb0355","doi-asserted-by":"crossref","first-page":"pkaa060","DOI":"10.1093\/jncics\/pkaa060","article-title":"Racial and ethnic disparities among participants in US-based phase 3 randomized cancer clinical trials","volume":"4","author":"Grant","year":"2020","journal-title":"JNCI Cancer Spectrum"},{"issue":"4","key":"10.1016\/j.jgo.2025.102321_bb0360","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/leu.2011.368","article-title":"Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites","volume":"26","author":"Greenberg","year":"2012","journal-title":"Leukemia"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406825001377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406825001377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:23:01Z","timestamp":1792394581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406825001377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1879406825001377"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2025.102321","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-related cognitive changes in multiple myeloma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2025.102321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102321"}}